AHA 25: Beta-Blocker Therapy Post MI in Patients with Preserved LVEF

17 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
AHA Scientific Sessions 2025 –

Dr Anna Meta Dyrvig Kristensen (Department of Cardiology, North Zealand Hospital, Hilleroed, DK) presents an individual patient data meta-analysis examining beta-blocker therapy after myocardial infarction in patients with preserved left ventricular ejection fraction.

This comprehensive meta-analysis pooled individual patient data from five randomized controlled trials: REBOOT, REDUCE-AMI, BETAMI, DANBLOCK, and CAPITAL-RCT - to evaluate the benefit of beta-blocker therapy in post-MI patients without left ventricular dysfunction.

Beta-blocker therapy did not reduce death, myocardial infarction, or heart failure in post-MI patients with preserved ejection fraction and no other indications for beta-blockers, with no significant benefit observed for any individual component of the composite endpoint including all-cause mortality, recurrent MI, or heart failure hospitalization.

Interview Questions:
1. What prompted this collaborative meta-analysis across multiple beta-blocker trials in post-MI patients?
2. Can you describe the included trials and the overall patient population analyzed?
3. What were the key findings regarding clinical outcomes with beta-blocker therapy in this population?
4. How should these findings influence clinical decision-making for beta-blocker prescribing after MI?
5. What are the implications for current guideline recommendations?

Visit our AHA 2025 Late-Breaking and Featured Science Collection page for more coverage.

Recorded on-site at AHA Scientific Sessions 2025, New Orleans.

Editor: Jordan Rance
Videographer: David Ben-Harosh

Support: This is an independent interview produced by Radcliffe Cardiology.

Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: https://www.facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO
Categoria
Cardiology
Commenta per primo questo video.

Prossimo